{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:32:23Z","timestamp":1792103543802,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chung-Ang University Gwangmyeong Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10120-026-01741-y","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T11:28:57Z","timestamp":1776598137000},"page":"788-797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intraperitoneal paclitaxel plus intravenous fluorouracil, leucovorin, oxaliplatin (FOLFOX) and nivolumab for gastric cancer with peritoneal metastasis: results from the IPLUS Phase II study"],"prefix":"10.1007","volume":"29","author":[{"given":"So Hyun","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjae","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woochan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Jeong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa-Hong","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Suk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Suhk","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Seung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-0048","authenticated-orcid":false,"given":"Hyung-Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"key":"1741_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1741_CR2","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population\u2010based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622\u20138. https:\/\/doi.org\/10.1002\/ijc.28373.","journal-title":"Int J Cancer"},{"key":"1741_CR3","doi-asserted-by":"publisher","first-page":"52307","DOI":"10.18632\/oncotarget.10740","volume":"7","author":"M Riihim\u00e4ki","year":"2016","unstructured":"Riihim\u00e4ki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget. 2016;7:52307\u201316. https:\/\/doi.org\/10.18632\/oncotarget.10740.","journal-title":"Oncotarget"},{"key":"1741_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10120-016-0662-9","volume":"20","author":"D Kobayashi","year":"2017","unstructured":"Kobayashi D, Kodera Y. Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Gastric Cancer. 2017;20:111\u201321. https:\/\/doi.org\/10.1007\/s10120-016-0662-9.","journal-title":"Gastric Cancer"},{"key":"1741_CR5","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/jjco\/hyt114","volume":"43","author":"K Shirao","year":"2013","unstructured":"Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, et al. Randomized Phase III study of 5-Fluorouracil continuous infusion vs. sequential methotrexate and 5-Fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 2013;43:972\u201380. https:\/\/doi.org\/10.1093\/jjco\/hyt114.","journal-title":"Jpn J Clin Oncol"},{"key":"1741_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/s1470-2045(21)00692-6","volume":"23","author":"Y-K Kang","year":"2022","unstructured":"Kang Y-K, Chen L-T, Ryu M-H, Oh D-Y, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234\u201347. https:\/\/doi.org\/10.1016\/s1470-2045(21)00692-6.","journal-title":"Lancet Oncol"},{"key":"1741_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(21)00797-2.","journal-title":"Lancet"},{"key":"1741_CR8","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1\u201311.","journal-title":"Cancer Treat Rep"},{"key":"1741_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00280-002-0439-1","volume":"49","author":"P Marchettini","year":"2002","unstructured":"Marchettini P, Stuart AO, Mohamed F, Yoo D, Sugarbaker PH. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Pharmacol. 2002;49:499\u2013503. https:\/\/doi.org\/10.1007\/s00280-002-0439-1.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1741_CR10","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s10120-025-01631-9","volume":"28","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Kitayama J, Kim H-H, So JB-Y, Cao H, Chen L, et al. Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis. Gastric Cancer. 2025;28:731\u201348. https:\/\/doi.org\/10.1007\/s10120-025-01631-9.","journal-title":"Gastric Cancer"},{"key":"1741_CR11","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/jco.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36:1922\u20139. https:\/\/doi.org\/10.1200\/jco.2018.77.8613.","journal-title":"J Clin Oncol"},{"key":"1741_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae116","volume":"111","author":"NAD Guchelaar","year":"2024","unstructured":"Guchelaar NAD, Nasserinejad K, Mostert B, Koolen SLW, van der Sluis PC, Lagarde SM, et al. Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: a systematic review and meta-analysis. Br J Surg. 2024;111:znae116. https:\/\/doi.org\/10.1093\/bjs\/znae116.","journal-title":"Br J Surg"},{"key":"1741_CR13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11582-5","author":"SH Kang","year":"2022","unstructured":"Kang SH, Min S-H, Kim JW, Lee E, Park SW, Lee S, et al. Safety and efficacy of intraperitoneal Paclitaxel plus intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for gastric cancer with peritoneal metastasis. Ann Surg Oncol. 2022. https:\/\/doi.org\/10.1245\/s10434-022-11582-5.","journal-title":"Ann Surg Oncol"},{"key":"1741_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1515\/pp-2016-0011","volume":"1","author":"W Solass","year":"2016","unstructured":"Solass W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Peritoneum. 2016;1:99\u2013107. https:\/\/doi.org\/10.1515\/pp-2016-0011.","journal-title":"Pleura Peritoneum"},{"key":"1741_CR15","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1200\/jco.2015.60.7465","volume":"33","author":"MA Shah","year":"2015","unstructured":"Shah MA, Janjigian YY, Stoller R, Shibata S, Kemeny M, Krishnamurthi S, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. J Clin Oncol. 2015;33:3874\u20139. https:\/\/doi.org\/10.1200\/jco.2015.60.7465.","journal-title":"J Clin Oncol"},{"key":"1741_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11605-016-3336-3","volume":"21","author":"DYS Chan","year":"2017","unstructured":"Chan DYS, Syn NL-X, Yap R, Phua JNS, Soh TIP, Chee CE, et al. Conversion surgery post-intraperitoneal Paclitaxel and systemic chemotherapy for gastric cancer carcinomatosis peritonei. Are we ready? J Gastrointest Surg. 2017;21:425\u201333. https:\/\/doi.org\/10.1007\/s11605-016-3336-3.","journal-title":"J Gastrointest Surg"},{"key":"1741_CR17","doi-asserted-by":"publisher","first-page":"8301","DOI":"10.2147\/ott.s184665","volume":"11","author":"H Osumi","year":"2018","unstructured":"Osumi H, Takahari D, Chin K, Ogura M, Ichimura T, Wakatsuki T, et al. Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake. Oncotargets Ther. 2018;11:8301\u20137. https:\/\/doi.org\/10.2147\/ott.s184665.","journal-title":"Oncotargets Ther"},{"key":"1741_CR18","doi-asserted-by":"publisher","first-page":"7037","DOI":"10.21873\/anticanres.12174","volume":"37","author":"T Masuishi","year":"2017","unstructured":"Masuishi T, Kadowaki S, Kondo M, Komori A, Sugiyama K, Mitani S, et al. FOLFOX as first-line therapy for gastric cancer with severe peritoneal metastasis. Anticancer Res. 2017;37:7037\u201342. https:\/\/doi.org\/10.21873\/anticanres.12174.","journal-title":"Anticancer Res"},{"key":"1741_CR19","doi-asserted-by":"publisher","first-page":"S231","DOI":"10.21037\/jgo-2020-03","volume":"12","author":"PH Sugarbaker","year":"2020","unstructured":"Sugarbaker PH. Intraperitoneal paclitaxel: pharmacology, clinical results and future prospects. J Gastrointest Oncol. 2020;12:S231\u20139. https:\/\/doi.org\/10.21037\/jgo-2020-03.","journal-title":"J Gastrointest Oncol"},{"key":"1741_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00280-004-0966-z","volume":"55","author":"R Tanaka","year":"2005","unstructured":"Tanaka R, Ariyama H, Qin B, Takii Y, Baba E, Mitsugi K, et al. In vitro schedule-dependent interaction between Paclitaxel and Oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol. 2005;55:595\u2013601. https:\/\/doi.org\/10.1007\/s00280-004-0966-z.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1741_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5230\/jgc.2023.23.e11","volume":"23","author":"T-H Kim","year":"2023","unstructured":"Kim T-H, Kim I-H, Kang SJ, Choi M, Kim B-H, Eom BW, et al. Korean practice guidelines for Gastric Cancer 2022: an evidence-based, multidisciplinary approach. J Gastric Cancer. 2023;23:3\u2013106. https:\/\/doi.org\/10.5230\/jgc.2023.23.e11.","journal-title":"J Gastric Cancer"},{"key":"1741_CR22","doi-asserted-by":"publisher","unstructured":"Associationjgca@koto.kpu-m.ac.jp JGC. Japanese Gastric cancer treatment guidelines 2021 (6th edition). Gastric cancer. 2022;1\u201325. https:\/\/doi.org\/10.1007\/s10120-022-01331-8","DOI":"10.1007\/s10120-022-01331-8"},{"key":"1741_CR23","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1245\/s10434-020-09388-4","volume":"28","author":"S Saito","year":"2021","unstructured":"Saito S, Yamaguchi H, Ohzawa H, Miyato H, Kanamaru R, Kurashina K, et al. Intraperitoneal administration of Paclitaxel combined with S-1 plus Oxaliplatin as induction therapy for patients with advanced Gastric Cancer with peritoneal metastases. Ann Surg Oncol. 2021;28:3863\u201370. https:\/\/doi.org\/10.1245\/s10434-020-09388-4.","journal-title":"Ann Surg Oncol"},{"key":"1741_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"S-E Al-Batran","year":"2017","unstructured":"Al-Batran S-E, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic Gastric or Gastroesophageal Junction Cancer: the AIO-FLOT3 Trial. JAMA Oncol. 2017;3:1237. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0515.","journal-title":"JAMA Oncol"},{"key":"1741_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","volume":"6","author":"K Yoshida","year":"2021","unstructured":"Yoshida K, Yasufuku I, Terashima M, Rha SY, Bae JM, Li G, et al. International retrospective cohort study of conversion therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2021;6:227\u201340. https:\/\/doi.org\/10.1002\/ags3.12515.","journal-title":"Ann Gastroenterol Surg"},{"key":"1741_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.109603","author":"WJ Seo","year":"2025","unstructured":"Seo WJ, Kim D-W, Lee CM, Park JY, Jang Y-J, Park J-M, et al. Intraperitoneal Paclitaxel with systemic S-1 plus Oxaliplatin for advanced or recurrent gastric cancer with peritoneal metastasis: a single-arm, multicenter phase II clinical trial. Eur J Surg Oncol. 2025. https:\/\/doi.org\/10.1016\/j.ejso.2025.109603.","journal-title":"Eur J Surg Oncol"},{"key":"1741_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/jco.2025.43.4_suppl.327","volume":"43","author":"C Yan","year":"2025","unstructured":"Yan C, Yang Z, Shi Z, Lu S, Shi M, Nie M, et al. Intraperitoneal and intravenous Paclitaxel plus S-1 versus intravenous Paclitaxel plus S-1 in Gastric Cancer patients with peritoneal metastasis: results from the multicenter, randomized, phase 3 DRAGON-01 trial. J Clin Oncol. 2025;43:327\u2013327. https:\/\/doi.org\/10.1200\/jco.2025.43.4_suppl.327.","journal-title":"J Clin Oncol"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01741-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-026-01741-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-026-01741-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:49:10Z","timestamp":1782715750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-026-01741-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,19]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1741"],"URL":"https:\/\/doi.org\/10.1007\/s10120-026-01741-y","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,19]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}